Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE atogepant in episodic migraine after failure of 2 to 4 oral preventive classes
NL-OMON52713Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine and episodic migraine comparing Atogepant 60 mg once daily with Placebo once daily (2 arms). Primary endpoint: Change from baseline in mean monthly migraine days across the 12-week treatment period. Started Oct 2021; status: active, not recruiting.
02
Drugs
atogepant
03
Conditions
migraineepisodic migraine
Beyond the preview
Go deeper on NL-OMON52713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52713.